NFKB1 and pulmonary arterial hypertension: The NF-κB signaling pathway is activated in the PAH model, and sevoflurane may inhibit the activation of the NF-κB signaling pathway by downregulating the levels of p-IκB, p-p65, and p65, thereby reducing pulmonary fibrosis and preventing PAH [55].